FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Powell Fred M 2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [ ATRS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Executive Vice President & CFO
(Last)         (First)         (Middle)
C/O ANTARES PHARMA, INC., 100 PRINCETON STREET SOUTH, SUITE 300
3. Date of Earliest Transaction (MM/DD/YYYY)
6/7/2020
(Street)
EWING, NJ 08628
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  6/7/2020    F(1)    9609 (1) D(1) $3.12  515444  D   
Common Stock  6/8/2020    F(1)    8683 (1) D(1) $3.13  506761  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Powell Fred M
C/O ANTARES PHARMA, INC.
100 PRINCETON STREET SOUTH, SUITE 300
EWING, NJ 08628


Executive Vice President & CFO

Signatures
/s/Keith Muckenhirn as attorney-in-fact for Fred M. Powell 6/9/2020
**Signature of Reporting Person Date
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Antares Pharma Charts.
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Antares Pharma Charts.